Skip to Content

Clinical Trials Detail

SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

Objective
This is a clinical trial of everolimus that will be administered by mouth which is investigational and hormone treatment that will be administered by mouth and subcutaneous injection and is standard of care.
IRB Protocol Number
13-1448
Principal Investigator(s)
ANTHONY ELIAS

Cancer Trials

  • Breast Cancer
Sponsor(s)
SWOG
Contact
CANDICE GILLMANN at 720-848-0663
or CANDICE.GILLMANN@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 54 weeks. A follow up period will consist of clinic visits. // Eligibility criteria include but are not limited to 18 years or older with breast cancer.